Global Chimeric Antigen Receptor T Cell Therapy Market Research Report 2024

Report ID: 1886001 | Published Date: Sep 2024 | No. of Page: 95 | Base Year: 2023 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Allogeneic
        1.2.3 Autologous
    1.3 Market by Application
        1.3.1 Global Chimeric Antigen Receptor T Cell Therapy Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Universities and Colleges
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Perspective (2017-2028)
    2.2 Chimeric Antigen Receptor T Cell Therapy Growth Trends by Region
        2.2.1 Chimeric Antigen Receptor T Cell Therapy Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Region (2017-2022)
        2.2.3 Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Region (2023-2028)
    2.3 Chimeric Antigen Receptor T Cell Therapy Market Dynamics
        2.3.1 Chimeric Antigen Receptor T Cell Therapy Industry Trends
        2.3.2 Chimeric Antigen Receptor T Cell Therapy Market Drivers
        2.3.3 Chimeric Antigen Receptor T Cell Therapy Market Challenges
        2.3.4 Chimeric Antigen Receptor T Cell Therapy Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Chimeric Antigen Receptor T Cell Therapy Players by Revenue
        3.1.1 Global Top Chimeric Antigen Receptor T Cell Therapy Players by Revenue (2017-2022)
        3.1.2 Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Players (2017-2022)
    3.2 Global Chimeric Antigen Receptor T Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Chimeric Antigen Receptor T Cell Therapy Revenue
    3.4 Global Chimeric Antigen Receptor T Cell Therapy Market Concentration Ratio
        3.4.1 Global Chimeric Antigen Receptor T Cell Therapy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Chimeric Antigen Receptor T Cell Therapy Revenue in 2021
    3.5 Chimeric Antigen Receptor T Cell Therapy Key Players Head office and Area Served
    3.6 Key Players Chimeric Antigen Receptor T Cell Therapy Product Solution and Service
    3.7 Date of Enter into Chimeric Antigen Receptor T Cell Therapy Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Chimeric Antigen Receptor T Cell Therapy Breakdown Data by Type
    4.1 Global Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Type (2017-2022)
    4.2 Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Type (2023-2028)
5 Chimeric Antigen Receptor T Cell Therapy Breakdown Data by Application
    5.1 Global Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Application (2017-2022)
    5.2 Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Chimeric Antigen Receptor T Cell Therapy Market Size (2017-2028)
    6.2 North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022)
    6.3 North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Chimeric Antigen Receptor T Cell Therapy Market Size (2017-2028)
    7.2 Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022)
    7.3 Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size (2017-2028)
    8.2 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022)
    8.3 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size (2017-2028)
    9.2 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022)
    9.3 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size (2017-2028)
    10.2 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022)
    10.3 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Amgen
        11.1.1 Amgen Company Detail
        11.1.2 Amgen Business Overview
        11.1.3 Amgen Chimeric Antigen Receptor T Cell Therapy Introduction
        11.1.4 Amgen Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.1.5 Amgen Recent Development
    11.2 Bellicum Pharmaceuticals
        11.2.1 Bellicum Pharmaceuticals Company Detail
        11.2.2 Bellicum Pharmaceuticals Business Overview
        11.2.3 Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Introduction
        11.2.4 Bellicum Pharmaceuticals Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.2.5 Bellicum Pharmaceuticals Recent Development
    11.3 Bluebird Bio
        11.3.1 Bluebird Bio Company Detail
        11.3.2 Bluebird Bio Business Overview
        11.3.3 Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Introduction
        11.3.4 Bluebird Bio Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.3.5 Bluebird Bio Recent Development
    11.4 Caribou Biosciences
        11.4.1 Caribou Biosciences Company Detail
        11.4.2 Caribou Biosciences Business Overview
        11.4.3 Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Introduction
        11.4.4 Caribou Biosciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.4.5 Caribou Biosciences Recent Development
    11.5 Celgene Corporation
        11.5.1 Celgene Corporation Company Detail
        11.5.2 Celgene Corporation Business Overview
        11.5.3 Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Introduction
        11.5.4 Celgene Corporation Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.5.5 Celgene Corporation Recent Development
    11.6 Cellectis
        11.6.1 Cellectis Company Detail
        11.6.2 Cellectis Business Overview
        11.6.3 Cellectis Chimeric Antigen Receptor T Cell Therapy Introduction
        11.6.4 Cellectis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.6.5 Cellectis Recent Development
    11.7 Celyad Oncology
        11.7.1 Celyad Oncology Company Detail
        11.7.2 Celyad Oncology Business Overview
        11.7.3 Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Introduction
        11.7.4 Celyad Oncology Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.7.5 Celyad Oncology Recent Development
    11.8 Gilead Sciences
        11.8.1 Gilead Sciences Company Detail
        11.8.2 Gilead Sciences Business Overview
        11.8.3 Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Introduction
        11.8.4 Gilead Sciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.8.5 Gilead Sciences Recent Development
    11.9 Intellia Therapeutics
        11.9.1 Intellia Therapeutics Company Detail
        11.9.2 Intellia Therapeutics Business Overview
        11.9.3 Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Introduction
        11.9.4 Intellia Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.9.5 Intellia Therapeutics Recent Development
    11.10 Johnson & Johnson
        11.10.1 Johnson & Johnson Company Detail
        11.10.2 Johnson & Johnson Business Overview
        11.10.3 Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Introduction
        11.10.4 Johnson & Johnson Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.10.5 Johnson & Johnson Recent Development
    11.11 Legend Biotech
        11.11.1 Legend Biotech Company Detail
        11.11.2 Legend Biotech Business Overview
        11.11.3 Legend Biotech Chimeric Antigen Receptor T Cell Therapy Introduction
        11.11.4 Legend Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.11.5 Legend Biotech Recent Development
    11.12 Merck
        11.12.1 Merck Company Detail
        11.12.2 Merck Business Overview
        11.12.3 Merck Chimeric Antigen Receptor T Cell Therapy Introduction
        11.12.4 Merck Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.12.5 Merck Recent Development
    11.13 Noile-Immune Biotech
        11.13.1 Noile-Immune Biotech Company Detail
        11.13.2 Noile-Immune Biotech Business Overview
        11.13.3 Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Introduction
        11.13.4 Noile-Immune Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.13.5 Noile-Immune Biotech Recent Development
    11.14 Novartis
        11.14.1 Novartis Company Detail
        11.14.2 Novartis Business Overview
        11.14.3 Novartis Chimeric Antigen Receptor T Cell Therapy Introduction
        11.14.4 Novartis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.14.5 Novartis Recent Development
    11.15 Pfizer
        11.15.1 Pfizer Company Detail
        11.15.2 Pfizer Business Overview
        11.15.3 Pfizer Chimeric Antigen Receptor T Cell Therapy Introduction
        11.15.4 Pfizer Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.15.5 Pfizer Recent Development
    11.16 Sangamo Therapeutics
        11.16.1 Sangamo Therapeutics Company Detail
        11.16.2 Sangamo Therapeutics Business Overview
        11.16.3 Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Introduction
        11.16.4 Sangamo Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.16.5 Sangamo Therapeutics Recent Development
    11.17 Servier Laboratories
        11.17.1 Servier Laboratories Company Detail
        11.17.2 Servier Laboratories Business Overview
        11.17.3 Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Introduction
        11.17.4 Servier Laboratories Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
        11.17.5 Servier Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Allogeneic
    Table 3. Key Players of Autologous
    Table 4. Global Chimeric Antigen Receptor T Cell Therapy Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 5. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Region (2017-2022)
    Table 8. Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Region (2023-2028)
    Table 10. Chimeric Antigen Receptor T Cell Therapy Market Trends
    Table 11. Chimeric Antigen Receptor T Cell Therapy Market Drivers
    Table 12. Chimeric Antigen Receptor T Cell Therapy Market Challenges
    Table 13. Chimeric Antigen Receptor T Cell Therapy Market Restraints
    Table 14. Global Chimeric Antigen Receptor T Cell Therapy Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Players (2017-2022)
    Table 16. Global Top Chimeric Antigen Receptor T Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chimeric Antigen Receptor T Cell Therapy as of 2021)
    Table 17. Ranking of Global Top Chimeric Antigen Receptor T Cell Therapy Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by Chimeric Antigen Receptor T Cell Therapy Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Chimeric Antigen Receptor T Cell Therapy Product Solution and Service
    Table 21. Date of Enter into Chimeric Antigen Receptor T Cell Therapy Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Type (2017-2022)
    Table 25. Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Type (2023-2028)
    Table 27. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Application (2017-2022)
    Table 29. Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Application (2023-2028)
    Table 31. North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 32. North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 33. Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 34. Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2017-2022) & (US$ Million)
    Table 36. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2023-2028) & (US$ Million)
    Table 37. Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 38. Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Amgen Company Detail
    Table 42. Amgen Business Overview
    Table 43. Amgen Chimeric Antigen Receptor T Cell Therapy Product
    Table 44. Amgen Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 45. Amgen Recent Development
    Table 46. Bellicum Pharmaceuticals Company Detail
    Table 47. Bellicum Pharmaceuticals Business Overview
    Table 48. Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Product
    Table 49. Bellicum Pharmaceuticals Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 50. Bellicum Pharmaceuticals Recent Development
    Table 51. Bluebird Bio Company Detail
    Table 52. Bluebird Bio Business Overview
    Table 53. Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Product
    Table 54. Bluebird Bio Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 55. Bluebird Bio Recent Development
    Table 56. Caribou Biosciences Company Detail
    Table 57. Caribou Biosciences Business Overview
    Table 58. Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Product
    Table 59. Caribou Biosciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 60. Caribou Biosciences Recent Development
    Table 61. Celgene Corporation Company Detail
    Table 62. Celgene Corporation Business Overview
    Table 63. Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Product
    Table 64. Celgene Corporation Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 65. Celgene Corporation Recent Development
    Table 66. Cellectis Company Detail
    Table 67. Cellectis Business Overview
    Table 68. Cellectis Chimeric Antigen Receptor T Cell Therapy Product
    Table 69. Cellectis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 70. Cellectis Recent Development
    Table 71. Celyad Oncology Company Detail
    Table 72. Celyad Oncology Business Overview
    Table 73. Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Product
    Table 74. Celyad Oncology Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 75. Celyad Oncology Recent Development
    Table 76. Gilead Sciences Company Detail
    Table 77. Gilead Sciences Business Overview
    Table 78. Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Product
    Table 79. Gilead Sciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 80. Gilead Sciences Recent Development
    Table 81. Intellia Therapeutics Company Detail
    Table 82. Intellia Therapeutics Business Overview
    Table 83. Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Product
    Table 84. Intellia Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 85. Intellia Therapeutics Recent Development
    Table 86. Johnson & Johnson Company Detail
    Table 87. Johnson & Johnson Business Overview
    Table 88. Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Product
    Table 89. Johnson & Johnson Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 90. Johnson & Johnson Recent Development
    Table 91. Legend Biotech Company Detail
    Table 92. Legend Biotech Business Overview
    Table 93. Legend Biotech Chimeric Antigen Receptor T Cell TherapyProduct
    Table 94. Legend Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 95. Legend Biotech Recent Development
    Table 96. Merck Company Detail
    Table 97. Merck Business Overview
    Table 98. Merck Chimeric Antigen Receptor T Cell TherapyProduct
    Table 99. Merck Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 100. Merck Recent Development
    Table 101. Noile-Immune Biotech Company Detail
    Table 102. Noile-Immune Biotech Business Overview
    Table 103. Noile-Immune Biotech Chimeric Antigen Receptor T Cell TherapyProduct
    Table 104. Noile-Immune Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 105. Noile-Immune Biotech Recent Development
    Table 106. Novartis Company Detail
    Table 107. Novartis Business Overview
    Table 108. Novartis Chimeric Antigen Receptor T Cell TherapyProduct
    Table 109. Novartis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 110. Novartis Recent Development
    Table 111. Pfizer Company Detail
    Table 112. Pfizer Business Overview
    Table 113. Pfizer Chimeric Antigen Receptor T Cell TherapyProduct
    Table 114. Pfizer Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 115. Pfizer Recent Development
    Table 116. Sangamo Therapeutics Company Detail
    Table 117. Sangamo Therapeutics Business Overview
    Table 118. Sangamo Therapeutics Chimeric Antigen Receptor T Cell TherapyProduct
    Table 119. Sangamo Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 120. Sangamo Therapeutics Recent Development
    Table 121. Servier Laboratories Company Detail
    Table 122. Servier Laboratories Business Overview
    Table 123. Servier Laboratories Chimeric Antigen Receptor T Cell TherapyProduct
    Table 124. Servier Laboratories Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022) & (US$ Million)
    Table 125. Servier Laboratories Recent Development
    Table 126. Research Programs/Design for This Report
    Table 127. Key Data Information from Secondary Sources
    Table 128. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Type: 2021 VS 2028
    Figure 2. Allogeneic Features
    Figure 3. Autologous Features
    Figure 4. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Application in 2021 & 2028
    Figure 5. Hospitals Case Studies
    Figure 6. Universities and Colleges Case Studies
    Figure 7. Others Case Studies
    Figure 8. Chimeric Antigen Receptor T Cell Therapy Report Years Considered
    Figure 9. Global Chimeric Antigen Receptor T Cell Therapy Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 10. Global Chimeric Antigen Receptor T Cell Therapy Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Region: 2021 VS 2028
    Figure 12. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Players in 2021
    Figure 13. Global Top Chimeric Antigen Receptor T Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chimeric Antigen Receptor T Cell Therapy as of 2021)
    Figure 14. The Top 10 and 5 Players Market Share by Chimeric Antigen Receptor T Cell Therapy Revenue in 2021
    Figure 15. North America Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 16. North America Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2017-2028)
    Figure 17. United States Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. Canada Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Europe Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2017-2028)
    Figure 21. Germany Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. France Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. U.K. Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Italy Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Russia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Nordic Countries Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Share by Region (2017-2028)
    Figure 29. China Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Japan Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. South Korea Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Southeast Asia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. India Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Australia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Latin America Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2017-2028)
    Figure 37. Mexico Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Brazil Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2017-2028)
    Figure 41. Turkey Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Saudi Arabia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Amgen Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 44. Bellicum Pharmaceuticals Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 45. Bluebird Bio Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 46. Caribou Biosciences Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 47. Celgene Corporation Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 48. Cellectis Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 49. Celyad Oncology Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 50. Gilead Sciences Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 51. Intellia Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 52. Johnson & Johnson Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 53. Legend Biotech Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 54. Merck Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 55. Noile-Immune Biotech Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 56. Novartis Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 57. Pfizer Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 58. Sangamo Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 59. Servier Laboratories Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2017-2022)
    Figure 60. Bottom-up and Top-down Approaches for This Report
    Figure 61. Data Triangulation
    Figure 62. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Amgen
Bellicum Pharmaceuticals
Bluebird Bio
Caribou Biosciences
Celgene Corporation
Cellectis
Celyad Oncology
Gilead Sciences
Intellia Therapeutics
Johnson & Johnson
Legend Biotech
Merck
Noile-Immune Biotech
Novartis
Pfizer
Sangamo Therapeutics
Servier Laboratories
Frequently Asked Questions
Chimeric Antigen Receptor T Cell Therapy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Chimeric Antigen Receptor T Cell Therapy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Chimeric Antigen Receptor T Cell Therapy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports